Reoperative Retroperitoneal Surgery - 15/08/11
, Pramod Sogani, MD, FACS a, b
Corresponding author. Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, 353 East 68th Street, New York, NY 10021.Abstract |
Although RPLND is both a diagnostic and therapeutic procedure, it must be performed with therapeutic intent. Adequacy of initial RPLND is a prognostic variable for clinical outcome. Effective cisplatin-based chemotherapy will not reliably compensate for suboptimal initial surgery. Many patients undergoing either primary RPLND or PC-RPLND will have unresected extratemplate disease if modified templates are used. Anatomic mapping studies, which provided the basis for modified templates, have significant limitations. Teratomatous elements are often found in the retroperitoneum of patients requiring reoperative surgery, which can be performed with acceptable morbidity in tertiary centers with experienced surgeons. The integration of chemotherapy and reoperative surgery can result in survival rates of almost 70% in patients with retroperitoneal relapse after initial suboptimal RPLND.
Le texte complet de cet article est disponible en PDF.Plan
Vol 34 - N° 2
P. 227-233 - mai 2007 Retour au numéro
Article précédent
- Post Chemotherapy RPLND in Patients with Elevated Markers: Current Concepts and Clinical Outcome
- Stephen D.W. Beck, Richard S. Foster, Richard Bihrle, Lawrence H. Einhorn, John P. Donohue
- Management of Non-Retroperitoneal Residual Germ Cell Tumor Masses
- Mark H. Katz, James M. McKiernan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?